{"id":10077,"date":"2026-06-22T11:00:00","date_gmt":"2026-06-22T15:00:00","guid":{"rendered":"https:\/\/progresso.com.br\/?p=10077"},"modified":"2026-06-22T10:36:20","modified_gmt":"2026-06-22T14:36:20","slug":"anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama","status":"publish","type":"post","link":"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/","title":{"rendered":"Anvisa aprova novo medicamento oral para c\u00e2ncer de mama"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong><em>Produto \u00e9 indicado para pacientes que foram previamente tratados com terapia end\u00f3crina<\/em><\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Ag\u00eancia Gov | Via Anvisa<\/em><br><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) publicou nesta segunda-feira (22\/6) o registro d&nbsp;o medicamento&nbsp;Inluriyo&nbsp;\u00ae&nbsp;(tosilato de&nbsp;inlunestranto).&nbsp;O produto \u00e9 indicado para&nbsp;adultos com&nbsp;c\u00e2ncer de mama&nbsp;localmente avan\u00e7ado, que n\u00e3o pode ser removido por cirurgia ou que j\u00e1 se espalhou para outras partes do corpo, e que foram previamente tratados com terapia end\u00f3crina.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Esse tipo de tumor apresenta as seguintes&nbsp;caracter\u00edsticas:&nbsp;\u00e9 positivo para receptor de estrog\u00eanio (ER+), negativo para receptor 2 do fator de crescimento epid\u00e9rmico humano (HER2-)&nbsp;e tem&nbsp;muta\u00e7\u00e3o no receptor de estrog\u00eanio 1 (ESR1m).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">O medicamento, desenvolvido pela Eli Lilly do Brasil Ltda.,&nbsp;\u00e9 oral e&nbsp;indicado como monoterapia.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">O&nbsp;c\u00e2ncer de&nbsp;mama \u00e9 a neoplasia maligna mais incidente em mulheres. No Brasil, de acordo com o Instituto Nacional do C\u00e2ncer (INCA)&nbsp;,&nbsp;no per\u00edodo&nbsp;de&nbsp;2023&nbsp;a&nbsp;2025, foram registrados&nbsp;73.610&nbsp;casos&nbsp;da doen\u00e7a, o que representa 30,1% dos c\u00e2nceres em mulheres.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Leia a&nbsp;<a href=\"https:\/\/www.in.gov.br\/web\/dou\/-\/resolucao-re-n-2.465-de-18-de-junho-de-2026-713601467https:\/\/www.in.gov.br\/web\/dou\/-\/resolucao-re-n-2.465-de-18-de-junho-de-2026-713601467\" rel=\"noreferrer noopener\" target=\"_blank\">Resolu\u00e7\u00e3o&nbsp;2.465\/&nbsp;2026&nbsp;<\/a>no Di\u00e1rio Oficial da Uni\u00e3o (DOU).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Produto \u00e9 indicado para pacientes que foram previamente tratados com terapia end\u00f3crina Ag\u00eancia Gov | Via Anvisa A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) publicou nesta segunda-feira (22\/6) o registro d&nbsp;o medicamento&nbsp;Inluriyo&nbsp;\u00ae&nbsp;(tosilato de&nbsp;inlunestranto).&nbsp;O produto \u00e9 indicado para&nbsp;adultos com&nbsp;c\u00e2ncer de mama&nbsp;localmente avan\u00e7ado, que n\u00e3o pode ser removido por cirurgia ou que j\u00e1 se espalhou para outras [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":10078,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13,2],"tags":[],"class_list":["post-10077","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cotidiano","category-destaque"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.1.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Anvisa aprova novo medicamento oral para c\u00e2ncer de mama - O PROGRESSO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anvisa aprova novo medicamento oral para c\u00e2ncer de mama - O PROGRESSO\" \/>\n<meta property=\"og:description\" content=\"Produto \u00e9 indicado para pacientes que foram previamente tratados com terapia end\u00f3crina Ag\u00eancia Gov | Via Anvisa A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) publicou nesta segunda-feira (22\/6) o registro d&nbsp;o medicamento&nbsp;Inluriyo&nbsp;\u00ae&nbsp;(tosilato de&nbsp;inlunestranto).&nbsp;O produto \u00e9 indicado para&nbsp;adultos com&nbsp;c\u00e2ncer de mama&nbsp;localmente avan\u00e7ado, que n\u00e3o pode ser removido por cirurgia ou que j\u00e1 se espalhou para outras [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/\" \/>\n<meta property=\"og:site_name\" content=\"O PROGRESSO\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/share\/1CeoksKBj6\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-22T15:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/06\/a3c4b235-2fc4-48fb-99e5-34f9e9154eba.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"500\" \/>\n\t<meta property=\"og:image:height\" content=\"329\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Rose\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Rose\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/\"},\"author\":{\"name\":\"Rose\",\"@id\":\"https:\/\/progresso.com.br\/#\/schema\/person\/5dd27138d4463fbbaace62120bfc002b\"},\"headline\":\"Anvisa aprova novo medicamento oral para c\u00e2ncer de mama\",\"datePublished\":\"2026-06-22T15:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/\"},\"wordCount\":227,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/progresso.com.br\/#organization\"},\"image\":{\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/06\/a3c4b235-2fc4-48fb-99e5-34f9e9154eba.jpeg\",\"articleSection\":[\"Cotidiano\",\"Em destaque\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/\",\"url\":\"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/\",\"name\":\"Anvisa aprova novo medicamento oral para c\u00e2ncer de mama - O PROGRESSO\",\"isPartOf\":{\"@id\":\"https:\/\/progresso.com.br\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/06\/a3c4b235-2fc4-48fb-99e5-34f9e9154eba.jpeg\",\"datePublished\":\"2026-06-22T15:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/#primaryimage\",\"url\":\"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/06\/a3c4b235-2fc4-48fb-99e5-34f9e9154eba.jpeg\",\"contentUrl\":\"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/06\/a3c4b235-2fc4-48fb-99e5-34f9e9154eba.jpeg\",\"width\":500,\"height\":329,\"caption\":\"O medicamento, desenvolvido pela Eli Lilly do Brasil Ltda., \u00e9 oral e indicado como monoterapia. foto: divulga\u00e7\u00e3o\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\/\/progresso.com.br\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anvisa aprova novo medicamento oral para c\u00e2ncer de mama\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/progresso.com.br\/#website\",\"url\":\"https:\/\/progresso.com.br\/\",\"name\":\"O PROGRESSO\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/progresso.com.br\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/progresso.com.br\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/progresso.com.br\/#organization\",\"name\":\"O PROGRESSO\",\"url\":\"https:\/\/progresso.com.br\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/progresso.com.br\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/03\/logo_proog.jpg\",\"contentUrl\":\"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/03\/logo_proog.jpg\",\"width\":1960,\"height\":1080,\"caption\":\"O PROGRESSO\"},\"image\":{\"@id\":\"https:\/\/progresso.com.br\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/share\/1CeoksKBj6\/\",\"https:\/\/www.instagram.com\/oprogresso_digital\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/progresso.com.br\/#\/schema\/person\/5dd27138d4463fbbaace62120bfc002b\",\"name\":\"Rose\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/progresso.com.br\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1b6890e759cdd3a88d9f751cb423720b9861c5239167cd3586355638b6556599?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1b6890e759cdd3a88d9f751cb423720b9861c5239167cd3586355638b6556599?s=96&d=mm&r=g\",\"caption\":\"Rose\"},\"url\":\"https:\/\/progresso.com.br\/index.php\/author\/rose\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anvisa aprova novo medicamento oral para c\u00e2ncer de mama - O PROGRESSO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/","og_locale":"pt_BR","og_type":"article","og_title":"Anvisa aprova novo medicamento oral para c\u00e2ncer de mama - O PROGRESSO","og_description":"Produto \u00e9 indicado para pacientes que foram previamente tratados com terapia end\u00f3crina Ag\u00eancia Gov | Via Anvisa A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) publicou nesta segunda-feira (22\/6) o registro d&nbsp;o medicamento&nbsp;Inluriyo&nbsp;\u00ae&nbsp;(tosilato de&nbsp;inlunestranto).&nbsp;O produto \u00e9 indicado para&nbsp;adultos com&nbsp;c\u00e2ncer de mama&nbsp;localmente avan\u00e7ado, que n\u00e3o pode ser removido por cirurgia ou que j\u00e1 se espalhou para outras [&hellip;]","og_url":"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/","og_site_name":"O PROGRESSO","article_publisher":"https:\/\/www.facebook.com\/share\/1CeoksKBj6\/","article_published_time":"2026-06-22T15:00:00+00:00","og_image":[{"width":500,"height":329,"url":"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/06\/a3c4b235-2fc4-48fb-99e5-34f9e9154eba.jpeg","type":"image\/jpeg"}],"author":"Rose","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Rose","Est. tempo de leitura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/#article","isPartOf":{"@id":"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/"},"author":{"name":"Rose","@id":"https:\/\/progresso.com.br\/#\/schema\/person\/5dd27138d4463fbbaace62120bfc002b"},"headline":"Anvisa aprova novo medicamento oral para c\u00e2ncer de mama","datePublished":"2026-06-22T15:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/"},"wordCount":227,"commentCount":0,"publisher":{"@id":"https:\/\/progresso.com.br\/#organization"},"image":{"@id":"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/#primaryimage"},"thumbnailUrl":"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/06\/a3c4b235-2fc4-48fb-99e5-34f9e9154eba.jpeg","articleSection":["Cotidiano","Em destaque"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/","url":"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/","name":"Anvisa aprova novo medicamento oral para c\u00e2ncer de mama - O PROGRESSO","isPartOf":{"@id":"https:\/\/progresso.com.br\/#website"},"primaryImageOfPage":{"@id":"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/#primaryimage"},"image":{"@id":"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/#primaryimage"},"thumbnailUrl":"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/06\/a3c4b235-2fc4-48fb-99e5-34f9e9154eba.jpeg","datePublished":"2026-06-22T15:00:00+00:00","breadcrumb":{"@id":"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/#primaryimage","url":"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/06\/a3c4b235-2fc4-48fb-99e5-34f9e9154eba.jpeg","contentUrl":"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/06\/a3c4b235-2fc4-48fb-99e5-34f9e9154eba.jpeg","width":500,"height":329,"caption":"O medicamento, desenvolvido pela Eli Lilly do Brasil Ltda., \u00e9 oral e indicado como monoterapia. foto: divulga\u00e7\u00e3o"},{"@type":"BreadcrumbList","@id":"https:\/\/progresso.com.br\/index.php\/2026\/06\/22\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/progresso.com.br\/"},{"@type":"ListItem","position":2,"name":"Anvisa aprova novo medicamento oral para c\u00e2ncer de mama"}]},{"@type":"WebSite","@id":"https:\/\/progresso.com.br\/#website","url":"https:\/\/progresso.com.br\/","name":"O PROGRESSO","description":"","publisher":{"@id":"https:\/\/progresso.com.br\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/progresso.com.br\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/progresso.com.br\/#organization","name":"O PROGRESSO","url":"https:\/\/progresso.com.br\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/progresso.com.br\/#\/schema\/logo\/image\/","url":"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/03\/logo_proog.jpg","contentUrl":"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/03\/logo_proog.jpg","width":1960,"height":1080,"caption":"O PROGRESSO"},"image":{"@id":"https:\/\/progresso.com.br\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/share\/1CeoksKBj6\/","https:\/\/www.instagram.com\/oprogresso_digital"]},{"@type":"Person","@id":"https:\/\/progresso.com.br\/#\/schema\/person\/5dd27138d4463fbbaace62120bfc002b","name":"Rose","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/progresso.com.br\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1b6890e759cdd3a88d9f751cb423720b9861c5239167cd3586355638b6556599?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1b6890e759cdd3a88d9f751cb423720b9861c5239167cd3586355638b6556599?s=96&d=mm&r=g","caption":"Rose"},"url":"https:\/\/progresso.com.br\/index.php\/author\/rose\/"}]}},"_links":{"self":[{"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/posts\/10077","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/comments?post=10077"}],"version-history":[{"count":1,"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/posts\/10077\/revisions"}],"predecessor-version":[{"id":10079,"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/posts\/10077\/revisions\/10079"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/media\/10078"}],"wp:attachment":[{"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/media?parent=10077"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/categories?post=10077"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/tags?post=10077"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}